In this episode of Executive Insights for Life Sciences Innovators, we speak with Charles Legg of CureLab Oncology, a biotechnology company developing novel immuno-oncology therapies designed to more precisely modulate immune pathways within the tumor microenvironment.

Charles shares his perspective on how immunotherapy continues to evolve beyond first-generation checkpoint inhibitors and why a deeper understanding of tumor biology may lead to more durable and broadly effective cancer treatments. We discuss the scientific rationale behind targeting immune signaling pathways, the challenges of translating complex biology into therapeutic development programs, and how emerging platform approaches may shape the future of oncology innovation.

We also explore the realities of building oncology companies in today’s capital environment, including capital efficiency, prioritization of development milestones, and how biotechnology leaders communicate complex scientific strategies to investors and partners.

This episode was streamed live on YouTube on April 6 2026. Learn more at ⁠⁠⁠⁠⁠⁠⁠genecoda.com⁠⁠⁠⁠⁠⁠⁠.